920 related articles for article (PubMed ID: 30652520)
1. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.
Wu JJ; Pelletier C; Ung B; Tian M
J Med Econ; 2019 Apr; 22(4):365-371. PubMed ID: 30652520
[TBL] [Abstract][Full Text] [Related]
2. Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis.
Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR
Adv Ther; 2020 May; 37(5):2098-2115. PubMed ID: 32141018
[TBL] [Abstract][Full Text] [Related]
3. Treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriatic arthritis: results from a US claims analysis.
Wu JJ; Pelletier C; Ung B; Tian M
Curr Med Res Opin; 2020 Jan; 36(1):169-176. PubMed ID: 31517542
[No Abstract] [Full Text] [Related]
4. Real-world switch patterns and healthcare costs in biologic-naive psoriasis patients initiating apremilast or biologics.
Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR
J Comp Eff Res; 2020 Aug; 9(11):767-779. PubMed ID: 32638609
[No Abstract] [Full Text] [Related]
5. Real-world US healthcare costs of psoriasis for biologic-naive patients initiating apremilast or biologics.
Feldman SR; Pelletier CL; Wilson KL; Mehta RK; Brouillette MA; Smith D; Bonafede MM
J Comp Eff Res; 2019 Jan; 8(1):45-54. PubMed ID: 30387367
[TBL] [Abstract][Full Text] [Related]
6. Treatment patterns and costs among biologic-naive patients initiating apremilast or biologics for psoriatic arthritis.
Feldman SR; Pelletier CL; Wilson KL; Mehta RK; Brouillette MA; Smith D; Bonafede MM
J Comp Eff Res; 2019 Jul; 8(9):699-709. PubMed ID: 31081676
[No Abstract] [Full Text] [Related]
7. Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs.
Murage MJ; Princic N; Park J; Malatestinic WN; Zhu B; Atiya B; Kern SA; Stenger KB; Sprabery AT; Ogdie A
J Manag Care Spec Pharm; 2022 Feb; 28(2):206-217. PubMed ID: 35098751
[No Abstract] [Full Text] [Related]
8. Real-World Experience With Apremilast in the Treatment of Adults With Moderate to Severe Plaque Psoriasis in Québec: A Claims-Based Analysis of Drug Utilization and Healthcare Resource Utilization.
Poulin Y; Beauchemin C; Royer C; Gaudreau AJ; Yim C; Liu FF; Lachaine J
J Cutan Med Surg; 2020; 24(6):573-587. PubMed ID: 32597685
[TBL] [Abstract][Full Text] [Related]
9. Switch Rates and Total Cost of Care Associated with Apremilast and Biologic Therapies in Biologic-Naive Patients with Plaque Psoriasis.
Kaplan DL; Ung BL; Pelletier C; Udeze C; Khilfeh I; Tian M
Clinicoecon Outcomes Res; 2020; 12():369-377. PubMed ID: 32765022
[TBL] [Abstract][Full Text] [Related]
10. Real-world treatment patterns and healthcare costs of biologics and apremilast among patients with moderate-to-severe plaque psoriasis by metabolic condition status.
Feldman SR; Zhang J; Martinez DJ; Lopez-Gonzalez L; Marchlewicz EH; Shrady G; Mendelsohn AM; Zhao Y
J Dermatolog Treat; 2021 Mar; 32(2):203-211. PubMed ID: 31769703
[TBL] [Abstract][Full Text] [Related]
11. Patient Characteristics, Health Care Resource Utilization, and Costs Associated with Treatment-Regimen Failure with Biologics in the Treatment of Psoriasis.
Foster SA; Zhu B; Guo J; Nikai E; Ojeh C; Malatestinic W; Goldblum O; Kornberg LJ; Wu JJ
J Manag Care Spec Pharm; 2016 Apr; 22(4):396-405. PubMed ID: 27023693
[TBL] [Abstract][Full Text] [Related]
12. Real-world biologic and apremilast treatment patterns and healthcare costs in moderate-to-severe plaque psoriasis.
Feldman SR; Zhang J; Martinez DJ; Lopez-Gonzalez L; Marchlewicz EH; Shrady G; Mendelsohn AM; Zhao Y
Dermatol Online J; 2021 Jan; 27(1):. PubMed ID: 33560784
[TBL] [Abstract][Full Text] [Related]
13. Persistence of apremilast in moderate-to-severe psoriasis: a real-world analysis of 14 147 apremilast- and methotrexate-naive patients in the French National Health Insurance database.
Sbidian E; Billionnet C; Weill A; Maura G; Mezzarobba M
Br J Dermatol; 2020 Mar; 182(3):690-697. PubMed ID: 31021438
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy of apremilast and biologics in patients with psoriasis showing biologic fatigue.
Takamura S; Sugai S; Taguchi R; Teraki Y
J Dermatol; 2020 Mar; 47(3):290-294. PubMed ID: 31867729
[TBL] [Abstract][Full Text] [Related]
15. Real-World Clinical Experience With Apremilast in a Large US Retrospective Cohort Study of Patients With Moderate to Severe Plaque Psoriasis.
Armstrong A; Levi E
J Drugs Dermatol; 2017 Dec; 16(12):1240-1245. PubMed ID: 29240859
[TBL] [Abstract][Full Text] [Related]
16. Switch rates and total cost associated with apremilast and biologics in biologic-naive patients with psoriatic arthritis.
Kaplan DL; Ung BL; Pelletier C; Udeze C; Khilfeh I; Tian M
J Comp Eff Res; 2021 Aug; 10(12):989-998. PubMed ID: 34187202
[No Abstract] [Full Text] [Related]
17. Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis.
Rubin DT; Mittal M; Davis M; Johnson S; Chao J; Skup M
J Manag Care Spec Pharm; 2017 Aug; 23(8):859-867. PubMed ID: 28737994
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study.
Reich K; Gooderham M; Bewley A; Green L; Soung J; Petric R; Marcsisin J; Cirulli J; Chen R; Piguet V
J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):397-402. PubMed ID: 29220542
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).
Reich K; Gooderham M; Green L; Bewley A; Zhang Z; Khanskaya I; Day RM; Goncalves J; Shah K; Piguet V; Soung J
J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):507-517. PubMed ID: 27768242
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy and incremental cost per responder of methotrexate versus apremilast for methotrexate-naïve patients with psoriasis.
Armstrong AW; Betts KA; Sundaram M; Thomason D; Signorovitch JE
J Am Acad Dermatol; 2016 Oct; 75(4):740-746. PubMed ID: 27476973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]